Innovacell Inc. Share Price

504A

JP3147850006

Pharmaceuticals

Market Closed - Japan Exchange 12:00:00 30/10/2026 pm IST			5-day change	1st Jan Change
498.00 ^JPY	+0.40%		+2.05%	-

22/08	Certain Common Stock of Innovacell Inc. are subject to a Lock-Up Agreement Ending on 22-AUG-2026.	CI
06/08	Innovacell Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Innovacell Inc. is a Japan-based company engaged in the development and manufacture of regenerative medicine products for fecal and urinary incontinence. The Company operates through the cell therapy and regenerative medicine research and development segment. The Company adopts a global aggregation model to identify pharmaceutical and medical device seeds worldwide, incorporate them into its pipeline, develop them and commercialize the resulting products in global markets. The Company focuses on pipelines consisting of human cell-based therapies. The Company is advancing three pipelines targeting urge fecal incontinence through ICEF15, passive fecal incontinence through ICEF16 and stress urinary incontinence through ICES13.

Employees

Sector

Pharmaceuticals

Calendar

11/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
30/26/30	JP¥498.00	+0.40%	49,900
29/26/29	JP¥496.00	-1.78%	1,21,400
28/26/28	JP¥505.00	+9.31%	1,74,200
27/26/27	JP¥462.00	-0.43%	65,800
26/26/26	JP¥464.00	-0.85%	83,700

Delayed Quote Japan Exchange

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Innovacell Inc.

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Innovacell Inc.

Company calendar

Stock Market
Stocks
504A Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	2.25TCr 14Cr 13Cr 12Cr 11Cr 20Cr 1.36TCr 20Cr 140.24Cr 56Cr 713.01Cr 54Cr 52Cr	P/E 2026 *	-6.11x	P/E 2027 *	-5.76x
Enterprise Value	2.25TCr 14Cr 13Cr 12Cr 11Cr 20Cr 1.36TCr 20Cr 140.24Cr 56Cr 713.01Cr 54Cr 52Cr	EV / Sales 2026 *	22.5x	EV / Sales 2027 *	20.9x
Free-Float	51.11%	Yield 2026 *	-	Yield 2027 *	-

22/08	Certain Common Stock of Innovacell Inc. are subject to a Lock-Up Agreement Ending on 22-AUG-2026.	CI
06/08	Innovacell Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06/08	Innovacell Inc. Provides Update on ICEF15 Multi-Regional Phase III Clinical Trial Enrollment and Completion of Patient Recruitment in Japan and Europe	CI
30/07	EVERSANA Inc. Selected By Innovacell Inc. As Commercialization Partner To Advance Novel Cell Therapy ICEF15 In The United States	CI
23/07	Innovacell Inc. Announces Execution of a Product Commercialization Agreement with EVERSANA Life Science Services, LLC for the U.S. Market	CI
02/07	Innovacell Secures U.S. Clearance for Global Phase III Cell Therapy Clinical Trial	MT
02/07	Innovacell Inc Announces Completion of FDA IND Review And Approval To Include U.S. Sites And Patients In ICEF15 Multi-Regional Phase III Fidelia Trial	CI
13/05	Innovacell Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/05	Innovacell Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2026	CI
24/02	Innovacell Inc. has completed an IPO in the amount of ¥12.319155 billion.	CI
24/02	Innovacell Forecasts Wider 2026 Loss After TSE Growth Listing	MT
24/02	Innovacell Targets Global Launch of Lead Cell Therapy After IPO	MT
24/02	Innovacell Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

1 day	+0.40%
1 week	+2.05%
Current month	-21.20%
1 month	-17.28%
3 months	-9.95%
6 months	-23.27%

1 week	450	520
1 month	450	632
Current year	377	1,248
1 year	377	1,248
3 years	377	1,248
5 years	377	1,248
10 years	377	1,248

Manager	Title	Age	Since
Colin Lee Novick CEO	Chief Executive Officer	45	01/03/2022
Jason Sieger CEO	Chief Executive Officer	44	01/03/2025
Yasushi Hosono DFI	Director of Finance/CFO	59	01/07/2021

Innovacell Inc. Share Price

Stocks

504A

JP3147850006

Pharmaceuticals

Valuation: Innovacell Inc.

Chart: Innovacell Inc.

Latest news: Innovacell Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Innovacell Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Director	Title	Age	Since
Jason Sieger BRD	Director/Board Member	44	01/01/2021
Colin Lee Novick BRD	Director/Board Member	45	01/07/2021
Rainer Marksteiner BRD	Director/Board Member	57	01/04/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INNOVACELL INC.	+0.40%	+2.05%	-	-	14Cr
ELI LILLY AND COMPANY	+3.19%	+8.48%	+74.25%	+153.03%	1,22400Cr
JOHNSON & JOHNSON	-0.73%	+2.09%	+46.41%	+87.64%	66TCr
ABBVIE INC.	+1.41%	+3.40%	+30.98%	+112.26%	51TCr
ROCHE HOLDING AG	+0.42%	+2.88%	+54.92%	+69.67%	39TCr
MERCK & CO., INC.	+2.18%	+1.55%	+72.70%	+45.42%	36TCr
NOVARTIS AG	+1.12%	+3.80%	+35.82%	+59.72%	30TCr
ASTRAZENECA PLC	+6.96%	+7.55%	+11.15%	+37.89%	27TCr
AMGEN INC.	+1.15%	+4.19%	+59.72%	+78.16%	25TCr
GILEAD SCIENCES, INC.	+3.06%	+8.58%	+44.03%	+122.76%	21TCr
Average	+1.98%	+2.50%	+47.77%	+85.17%	41.77TCr
Weighted average by Cap.	+1.95%	+3.04%	+53.35%	+100.42%

	2026 *	2027 *
Net sales	100Cr 63.49L 56.86L 52.3L 47.39L 88.58L 60Cr 90.24L 6.24Cr 2.5Cr 32Cr 2.38Cr 2.33Cr	107.8Cr 68.44L 61.29L 56.38L 51.09L 95.49L 65Cr 97.28L 6.72Cr 2.7Cr 34Cr 2.57Cr 2.51Cr
Net income	-346.3Cr -2.2Cr -1.97Cr -1.81Cr -1.64Cr -3.07Cr -208.75Cr -3.12Cr -22Cr -8.67Cr -109.81Cr -8.25Cr -8.08Cr	-380.8Cr -2.42Cr -2.17Cr -1.99Cr -1.8Cr -3.37Cr -229.55Cr -3.44Cr -24Cr -9.53Cr -120.75Cr -9.07Cr -8.88Cr
Net Debt	-	-